• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

循环微RNA-21对预测结直肠癌患者治疗后早期复发的潜在价值

Potential Values of Circulating microRNA-21 to Predict Early Recurrence in Patients with Colorectal Cancer after Treatments.

作者信息

Hao Yun-Jie, Yang Chih-Yung, Chen Ming-Hsien, Chang Lu-Wey, Lin Chien-Ping, Lo Liang-Chuan, Huang Sheng-Chieh, Lyu You-You, Jiang Jeng-Kai, Tseng Fan-Gang

机构信息

Department of Engineering and System Science, National Tsing Hua University, Hsinchu 30013, Taiwan.

School of Engineering, University of Liverpool, Liverpool L69 3BX, UK.

出版信息

J Clin Med. 2022 Apr 25;11(9):2400. doi: 10.3390/jcm11092400.

DOI:10.3390/jcm11092400
PMID:35566526
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9100254/
Abstract

Insufficient prognosis of local recurrence contributes to the poor progression-free survival rate and death in colorectal cancer (CRC) patients. Various biomarkers have been explored in predicting CRC recurrence. This study investigated the expressions of plasma/exosomal microRNA-21 (miR-21) in 113 CRC patients by qPCR, their values of predicting CRC recurrence, and the possibility to improve the prognostic efficacy in early CRC recurrence in stratified patients by combined biomarkers including circulating miR-21s, circulating tumour cells/microemboli (CTCs/CTM), and serum carcinoembryonic antigen (CEA)/carbohydrate antigen 19-9 (CA19-9). Expressions of plasma and exosomal miR-21s were significantly correlated (p < 0.0001) in all and late-stage patients, presenting similar correlations with other biomarkers. However, stage IV patients stratified by a high level of exosomal miR-21 and stage I to III patients stratified by a high level of plasma miR-21 displayed significantly worse survival outcomes in predicting CRC recurrence, suggesting their different values to predict CRC recurrence in stratified patients. Comparable and even better performances in predicting CRC recurrence in late-stage patients were found by CTCs/CTM from our blood samples as sensitive biomarkers. Improved prognosing efficacy in CRC recurrence and better outcomes to significantly differentiate recurrence in stratified patients could be obtained by analysing combined biomarkers.

摘要

局部复发的预后不足导致结直肠癌(CRC)患者无进展生存率低和死亡率高。人们已经探索了多种生物标志物来预测CRC复发。本研究通过qPCR检测了113例CRC患者血浆/外泌体微小RNA-21(miR-21)的表达、其预测CRC复发的价值,以及通过包括循环miR-21、循环肿瘤细胞/微栓子(CTCs/CTM)和血清癌胚抗原(CEA)/糖类抗原19-9(CA19-9)在内的联合生物标志物改善分层患者早期CRC复发预后疗效的可能性。在所有患者和晚期患者中,血浆和外泌体miR-21的表达显著相关(p<0.0001),与其他生物标志物呈现相似的相关性。然而,以外泌体miR-21高水平分层的IV期患者和以血浆miR-21高水平分层的I至III期患者在预测CRC复发时显示出显著更差的生存结果,表明它们在分层患者中预测CRC复发的价值不同。从我们的血样中发现,CTCs/CTM作为敏感生物标志物在预测晚期患者CRC复发方面具有相当甚至更好的表现。通过分析联合生物标志物,可以提高CRC复发的预后疗效,并在分层患者中更好地区分复发情况,从而获得更好的结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbdf/9100254/8c0d7e3c7e68/jcm-11-02400-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbdf/9100254/802998d1cb24/jcm-11-02400-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbdf/9100254/d0be4474ced1/jcm-11-02400-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbdf/9100254/7d016d0dd917/jcm-11-02400-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbdf/9100254/a0865eb76f31/jcm-11-02400-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbdf/9100254/b1335a641d28/jcm-11-02400-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbdf/9100254/8c0d7e3c7e68/jcm-11-02400-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbdf/9100254/802998d1cb24/jcm-11-02400-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbdf/9100254/d0be4474ced1/jcm-11-02400-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbdf/9100254/7d016d0dd917/jcm-11-02400-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbdf/9100254/a0865eb76f31/jcm-11-02400-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbdf/9100254/b1335a641d28/jcm-11-02400-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbdf/9100254/8c0d7e3c7e68/jcm-11-02400-g006.jpg

相似文献

1
Potential Values of Circulating microRNA-21 to Predict Early Recurrence in Patients with Colorectal Cancer after Treatments.循环微RNA-21对预测结直肠癌患者治疗后早期复发的潜在价值
J Clin Med. 2022 Apr 25;11(9):2400. doi: 10.3390/jcm11092400.
2
The rare circulating tumor microemboli as a biomarker contributes to predicting early colorectal cancer recurrences after medical treatment.罕见的循环肿瘤微栓子作为一种生物标志物有助于预测治疗后结直肠癌的早期复发。
Transl Res. 2024 Jan;263:1-14. doi: 10.1016/j.trsl.2023.07.011. Epub 2023 Aug 8.
3
Highly Correlated Recurrence Prognosis in Patients with Metastatic Colorectal Cancer by Synergistic Consideration of Circulating Tumor Cells/Microemboli and Tumor Markers CEA/CA19-9.循环肿瘤细胞/微栓与肿瘤标志物 CEA/CA19-9 协同考虑预测转移性结直肠癌患者的高复发预后。
Cells. 2021 May 10;10(5):1149. doi: 10.3390/cells10051149.
4
Prognostic models based on postoperative circulating tumor cells can predict poor tumor recurrence-free survival in patients with stage II-III colorectal cancer.基于术后循环肿瘤细胞的预后模型可以预测II-III期结直肠癌患者较差的无肿瘤复发生存率。
J Cancer. 2019 Jul 25;10(19):4552-4563. doi: 10.7150/jca.30512. eCollection 2019.
5
Synergistic diagnostic value of circulating tumor cells and tumor markers CEA/CA19-9 in colorectal cancer.循环肿瘤细胞与肿瘤标志物CEA/CA19-9在结直肠癌中的协同诊断价值
Scand J Gastroenterol. 2023 Jan;58(1):54-60. doi: 10.1080/00365521.2022.2106152. Epub 2022 Aug 14.
6
Circulating tumor microemboli (CTM) and vimentin+ circulating tumor cells (CTCs) detected by a size-based platform predict worse prognosis in advanced colorectal cancer patients during chemotherapy.通过基于大小的平台检测到的循环肿瘤微栓子(CTM)和波形蛋白阳性循环肿瘤细胞(CTC)可预测晚期结直肠癌患者化疗期间的预后较差。
Cancer Cell Int. 2017 Jan 5;17:6. doi: 10.1186/s12935-016-0373-7. eCollection 2017.
7
Plasma miR-183 predicts recurrence and prognosis in patients with colorectal cancer.血浆miR-183可预测结直肠癌患者的复发和预后。
Cancer Biol Ther. 2015;16(2):268-75. doi: 10.1080/15384047.2014.1002327.
8
Circulating Exosomal MicroRNA-21 as a Biomarker in Each Tumor Stage of Colorectal Cancer.循环外泌体微小RNA-21作为结直肠癌各肿瘤分期的生物标志物
Oncology. 2017;92(6):360-370. doi: 10.1159/000463387. Epub 2017 Apr 5.
9
Significant diagnostic value of circulating tumour cells in colorectal cancer.循环肿瘤细胞在结直肠癌中的重要诊断价值。
Oncol Lett. 2020 Jul;20(1):317-325. doi: 10.3892/ol.2020.11537. Epub 2020 Apr 15.
10
Enhanced prognostic value of combined circulating tumor cells and serum carcinoembryonic antigen in patients with colorectal cancer.循环肿瘤细胞与血清癌胚抗原联合检测对结直肠癌患者预后评估价值的增强
J Chin Med Assoc. 2023 May 1;86(5):465-471. doi: 10.1097/JCMA.0000000000000906. Epub 2023 Feb 23.

引用本文的文献

1
The Role of Epigenetic Biomarkers as Diagnostic, Predictive and Prognostic Factors in Colorectal Cancer.表观遗传生物标志物在结直肠癌中作为诊断、预测和预后因素的作用
Cancers (Basel). 2025 Aug 12;17(16):2632. doi: 10.3390/cancers17162632.
2
Prognostic value of extracellular vesicles in colorectal cancer: a systematic review and meta-analysis.细胞外囊泡在结直肠癌中的预后价值:一项系统评价和荟萃分析
Clin Transl Oncol. 2025 Apr 9. doi: 10.1007/s12094-025-03915-z.
3
Development and validation of a novel combinational index of liquid biopsy biomarker for longitudinal lung cancer patient management.

本文引用的文献

1
Characteristics and Clinical Application of Extracellular Vesicle-Derived DNA.细胞外囊泡衍生DNA的特征与临床应用
Cancers (Basel). 2021 Jul 29;13(15):3827. doi: 10.3390/cancers13153827.
2
Postoperative changes in plasma miR21-5p as a novel biomarker for colorectal cancer recurrence: A prospective study.血浆 miR21-5p 术后变化作为结直肠癌复发的新型生物标志物:一项前瞻性研究。
Cancer Sci. 2021 Oct;112(10):4270-4280. doi: 10.1111/cas.15065. Epub 2021 Aug 22.
3
Detection and Clinical Value of Circulating Tumor Cells as an Assisted Prognostic Marker in Colorectal Cancer Patients.
用于肺癌患者纵向管理的新型液体活检生物标志物组合指数的开发与验证
J Liq Biopsy. 2024 Sep 10;6:100167. doi: 10.1016/j.jlb.2024.100167. eCollection 2024 Dec.
4
A Preliminary Analysis of Circulating Tumor Microemboli from Breast Cancer Patients during Follow-Up Visits.对随访期间乳腺癌患者循环肿瘤微栓子的初步分析。
Curr Oncol. 2024 Sep 21;31(9):5677-5693. doi: 10.3390/curroncol31090421.
5
Gut microbiota and their derivatives in the progression of colorectal cancer: Mechanisms of action, genome and epigenome contributions.肠道微生物群及其衍生物在结直肠癌进展中的作用:作用机制、基因组和表观基因组的贡献
Heliyon. 2024 Apr 10;10(8):e29495. doi: 10.1016/j.heliyon.2024.e29495. eCollection 2024 Apr 30.
6
Lynch Syndrome Biopathology and Treatment: The Potential Role of microRNAs in Clinical Practice.林奇综合征的生物病理学与治疗:微小RNA在临床实践中的潜在作用
Cancers (Basel). 2023 Aug 2;15(15):3930. doi: 10.3390/cancers15153930.
7
Non-coding RNAs and gastrointestinal cancers prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies.非编码RNA与胃肠道癌症预后:观察性研究的系统评价和荟萃分析的综合评价
Front Oncol. 2023 Jul 20;13:1193665. doi: 10.3389/fonc.2023.1193665. eCollection 2023.
8
Exploring the Role of Circulating Cell-Free RNA in the Development of Colorectal Cancer.探讨循环无细胞 RNA 在结直肠癌发展中的作用。
Int J Mol Sci. 2023 Jul 3;24(13):11026. doi: 10.3390/ijms241311026.
9
Circulating exosomal microRNAs as potential prognostic biomarkers in gastrointestinal cancers: a systematic review and meta-analysis.循环外泌体微小RNA作为胃肠道癌症潜在的预后生物标志物:一项系统评价和荟萃分析
Cancer Cell Int. 2023 Jan 20;23(1):10. doi: 10.1186/s12935-023-02851-8.
循环肿瘤细胞作为结直肠癌患者辅助预后标志物的检测及临床价值
Cancer Manag Res. 2021 Jun 8;13:4567-4578. doi: 10.2147/CMAR.S300554. eCollection 2021.
4
Highly Correlated Recurrence Prognosis in Patients with Metastatic Colorectal Cancer by Synergistic Consideration of Circulating Tumor Cells/Microemboli and Tumor Markers CEA/CA19-9.循环肿瘤细胞/微栓与肿瘤标志物 CEA/CA19-9 协同考虑预测转移性结直肠癌患者的高复发预后。
Cells. 2021 May 10;10(5):1149. doi: 10.3390/cells10051149.
5
Enhancing Prediction Performance by Add-On Combining Circulating Tumor Cell Count, CD45 EpCAM Cell Count on Colorectal Cancer, Advance, and Metastasis.通过联合循环肿瘤细胞计数、结直肠癌中CD45⁺EpCAM⁺细胞计数来提高对结直肠癌进展和转移的预测性能
Cancers (Basel). 2021 May 21;13(11):2521. doi: 10.3390/cancers13112521.
6
Circulating miRNA as Biomarkers for Colorectal Cancer Diagnosis and Liver Metastasis.循环微小RNA作为结直肠癌诊断和肝转移的生物标志物
Diagnostics (Basel). 2021 Feb 19;11(2):341. doi: 10.3390/diagnostics11020341.
7
ACG Clinical Guidelines: Colorectal Cancer Screening 2021.ACG 临床指南:结直肠癌筛查 2021 年版。
Am J Gastroenterol. 2021 Mar 1;116(3):458-479. doi: 10.14309/ajg.0000000000001122.
8
Evaluation of prognostic factors and clinicopathological patterns of recurrence after curative surgery for colorectal cancer.结直肠癌根治性手术后复发的预后因素及临床病理模式评估。
World J Gastrointest Surg. 2021 Jan 27;13(1):50-75. doi: 10.4240/wjgs.v13.i1.50.
9
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
10
Colon capsule endoscopy in colorectal cancer screening: a systematic review.结直肠肿瘤筛查中胶囊结肠镜检查:系统评价。
Endoscopy. 2021 Aug;53(8):815-824. doi: 10.1055/a-1308-1297. Epub 2021 Jan 13.